$0.93
+0.11 (+13.15%)
Open$0.86
Previous Close$0.82
Day High$0.95
Day Low$0.82
52W High$2.64
52W Low$2.02
Volume—
Avg Volume657.5K
Market Cap24.46M
P/E Ratio21.83
EPS$0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+248.3% upside
Current
$0.93
$0.93
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.32M | 15.18M | 16.45M |
| Net Income | 933.1K | 1.21M | 962.0K |
| Profit Margin | 6.1% | 8.0% | 5.9% |
| EBITDA | 2.07M | 1.98M | 2.22M |
| Free Cash Flow | 922.5K | 1.07M | 1.04M |
| Rev Growth | -6.3% | +1.7% | +13.6% |
| Debt/Equity | 0.26 | 0.33 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |